These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26085073)

  • 1. [Treatment reduction in well-controlled rheumatoid arthritis. State of knowledge].
    Krüger K; Edelmann E
    Z Rheumatol; 2015 Jun; 74(5):414-20. PubMed ID: 26085073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rheumatoid arthritis].
    Aletaha D; Kerschbaumer A
    Z Rheumatol; 2017 Feb; 76(1):8-14. PubMed ID: 28058499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
    Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
    Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
    Schett G; Emery P; Tanaka Y; Burmester G; Pisetsky DS; Naredo E; Fautrel B; van Vollenhoven R
    Ann Rheum Dis; 2016 Aug; 75(8):1428-37. PubMed ID: 27261493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].
    Mallick A; Fautrel B; Sagez F; Sordet C; Javier RM; Petit H; Chatelus E; Rahal N; Gottenberg JE; Sibilia J
    Rev Med Interne; 2017 Apr; 38(4):256-263. PubMed ID: 28161110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic].
    Rubbert-Roth A
    Z Rheumatol; 2015 Jun; 74(5):406-13. PubMed ID: 26031285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
    Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
    J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
    Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
    Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott IC; Kingsley GH; Scott DL
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S4-8. PubMed ID: 24129128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era.
    Caporali R; Scirè CA; Todoerti M; Montecucco C
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S9-13. PubMed ID: 24129129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
    Nagy G; van Vollenhoven RF
    Arthritis Res Ther; 2015 Aug; 17(1):181. PubMed ID: 26235544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice.
    Lenert A; Lenert P
    Clin Rheumatol; 2017 Jan; 36(1):1-8. PubMed ID: 27896522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.
    Plasencia C; Wolbink G; Krieckaert CL; Kneepkens EL; Turk S; Jurado T; Martínez-Feito A; Navarro-Compán V; Bonilla G; Villalba A; Peiteado D; Nuño L; Martín-Mola E; Nurmohamed MT; van der Kleij D; Rispens T; Pascual-Salcedo D; Balsa A
    Clin Exp Rheumatol; 2016; 34(4):655-62. PubMed ID: 27214767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA].
    Albrecht K; Callhoff J; Edelmann E; Schett G; Schneider M; Zink A
    Z Rheumatol; 2016 Feb; 75(1):90-6. PubMed ID: 26680365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BeSt way of withdrawing biologic agents.
    Allaart CF; Lems WF; Huizinga TW
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials.
    Kavanaugh A; Smolen JS
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S19-21. PubMed ID: 24129131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.